201 related articles for article (PubMed ID: 34965958)
21. A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation.
Hess L; Moos V; Lauber AA; Reiter W; Schuster M; Hartl N; Lackner D; Boenke T; Koren A; Guzzardo PM; Gundacker B; Riegler A; Vician P; Miccolo C; Leiter S; Chandrasekharan MB; Vcelkova T; Tanzer A; Jun JQ; Bradner J; Brosch G; Hartl M; Bock C; Bürckstümmer T; Kubicek S; Chiocca S; Bhaskara S; Seiser C
PLoS Genet; 2022 Aug; 18(8):e1010376. PubMed ID: 35994477
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
Singh T; Prasad R; Katiyar SK
Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
[TBL] [Abstract][Full Text] [Related]
23. Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer.
Wan G; Feng Z; Zhang Q; Li X; Ran K; Feng H; Luo T; Zhou S; Su C; Wei W; Wang N; Gao C; Zhao L; Yu L
J Med Chem; 2022 Dec; 65(24):16541-16569. PubMed ID: 36449947
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
25. Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3.
Pufahl L; Katryniok C; Schnur N; Sorg BL; Metzner J; Grez M; Steinhilber D
J Cell Mol Med; 2012 Jul; 16(7):1461-73. PubMed ID: 21883892
[TBL] [Abstract][Full Text] [Related]
26. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
27. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
28. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
29. Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy.
Holay N; Somma A; Duchow M; Soleimani M; Capasso A; Kottapalli S; Rios J; Giri U; Diamond J; Schreiber A; Piscopio AD; Van Den Berg C; Eckhardt SG; Triplett TA
Front Immunol; 2023; 14():1260545. PubMed ID: 37744352
[TBL] [Abstract][Full Text] [Related]
30. [Histone modification and its application in therapy for hematologic malignancies -- review].
Fang MH; Ji XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):816-20. PubMed ID: 19549415
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of class I HDAC isoform selectivity of largazole analogues.
Kim B; Park H; Salvador LA; Serrano PE; Kwan JC; Zeller SL; Chen QY; Ryu S; Liu Y; Byeon S; Luesch H; Hong J
Bioorg Med Chem Lett; 2014 Aug; 24(16):3728-31. PubMed ID: 25070421
[TBL] [Abstract][Full Text] [Related]
32. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
Shankar S; Srivastava RK
Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
35. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
Korfei M; Mahavadi P; Guenther A
Cells; 2022 May; 11(10):. PubMed ID: 35626663
[TBL] [Abstract][Full Text] [Related]
36. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.
Banerji U; van Doorn L; Papadatos-Pastos D; Kristeleit R; Debnam P; Tall M; Stewart A; Raynaud F; Garrett MD; Toal M; Hooftman L; De Bono JS; Verweij J; Eskens FA
Clin Cancer Res; 2012 May; 18(9):2687-94. PubMed ID: 22553374
[TBL] [Abstract][Full Text] [Related]
37. HDACs as an emerging target in endocrine tumors: a comprehensive review.
Klieser E; Neumayer B; Di Fazio P; Mayr C; Neureiter D; Kiesslich T
Expert Rev Endocrinol Metab; 2023 Mar; 18(2):143-154. PubMed ID: 36872882
[TBL] [Abstract][Full Text] [Related]
38. The emerging roles of HDACs and their therapeutic implications in cancer.
Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
[TBL] [Abstract][Full Text] [Related]
39. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
Thurn KT; Thomas S; Moore A; Munster PN
Future Oncol; 2011 Feb; 7(2):263-83. PubMed ID: 21345145
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of largazole zinc-binding group analogs.
Kim B; Ratnayake R; Lee H; Shi G; Zeller SL; Li C; Luesch H; Hong J
Bioorg Med Chem; 2017 Jun; 25(12):3077-3086. PubMed ID: 28416100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
